Thermo Fisher reached the target price from our last report as the company had a solid quarter with revenues shooting up 34% and an organic growth of 28% as compared to the prior year's quarterly results. The company’s core business of diagnostics and healthcare were major contributors to this growth and are well to reach pre-pandemic levels. Its immunodiagnostics and transplant diagnostics businesses showed a particularly robust performance. However, Thermo Fisher witnessed a visible slowdown i ....
04 Aug 2021
Thermo Fisher Scientific Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Thermo Fisher Scientific Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation
- Published:
04 Aug 2021 -
Author:
Ishan Majumdar -
Pages:
14
Thermo Fisher reached the target price from our last report as the company had a solid quarter with revenues shooting up 34% and an organic growth of 28% as compared to the prior year's quarterly results. The company’s core business of diagnostics and healthcare were major contributors to this growth and are well to reach pre-pandemic levels. Its immunodiagnostics and transplant diagnostics businesses showed a particularly robust performance. However, Thermo Fisher witnessed a visible slowdown i ....